CDK 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment.

The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer.